Data from Roche’s Perjeta Study – Analyst Blog

By | December 10, 2012
0 Comment

Roche Holding ( RHHBY ) recently announced survival data from its phase III CLEOPATRA study on Perjeta (pertuzumab). Data from the study showed that Perjeta plus Roche’s existing breast

More:
Data from Roche’s Perjeta Study – Analyst Blog

Related posts:

  1. Phase III Data on Novartis’ RLX030 – Analyst Blog
  2. Encouraging Data on Glaxo’s Drug – Analyst Blog
  3. COV Presents Positive Study Results – Analyst Blog
  4. Positive Data on CYTK’s Tirasemtiv – Analyst Blog